Mediwound Stock Price, News & Analysis

MediWound (Nasdaq: MDWD) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) for NexoBrid®, its enzymatic therapy for eschar removal in adult and pediatric burn patients. This approval expands NexoBrid's global presence to 45 countries.

The company's exclusive partner, Balance Medical, plans to launch NexoBrid commercially in Q4 2025. MediWound's manufacturing expansion, scheduled for completion by year-end 2025, will support the Australian launch and growing global demand. The approval represents a strategic entry point into the broader Asia-Pacific market.

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, announced that its burn debridement therapy NexoBrid® will be featured in 36 scientific presentations at the 21st European Burns Association Congress in Berlin (September 3-6, 2025).

The presentations will showcase data demonstrating NexoBrid's benefits in various patient populations, including pediatric, elderly, and critically burned patients. Key findings highlight improvements in survival, recovery, and scar outcomes, along with advantages in infection control and inflammatory response modulation. Studies also demonstrate NexoBrid's superiority over surgical excision in both routine care and mass casualty scenarios.

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Ofer Gonen will engage in a fireside chat with Managing Director and Senior Equity Research Analyst Swayampakula Ramakanth on September 8, 2025, at 4:30 PM ET.

Investors can access the live webcast through the company's website in the Events & Presentations section of the Investors page.

MediWound (NASDAQ: MDWD), a leader in enzymatic therapeutics for tissue repair, reported Q2 2025 financial results with revenue of $5.7 million, up 43% from the previous quarter. The company highlighted progress in its VALUE Phase III trial of EscharEx® for venous leg ulcers and established new strategic partnerships with Essity and Convatec.

Key developments include NexoBrid®'s 52% year-over-year U.S. revenue growth and ongoing manufacturing expansion expected to increase production capacity six-fold by year-end 2025. The company received an additional $3.6 million in DoD funding for NexoBrid development. Financial results showed a net loss of $13.3 million, with cash reserves of $32.9 million as of June 30, 2025.

[ "Revenue increased 43% quarter-over-quarter to $5.7 million", "NexoBrid U.S. sales grew 52% year-over-year", "Secured $3.6 million additional DoD funding for NexoBrid development", "Manufacturing capacity expansion to increase NexoBrid production six-fold", "New strategic partnerships established with Essity and Convatec", "Gross margin improved to 23.5% from 8.8% year-over-year" ]

MediWound (Nasdaq: MDWD) has published new Phase II data analysis for EscharEx® in the treatment of venous leg ulcers (VLUs) in Advances in Wound Care journal. The study, analyzing 119 VLU patients, demonstrated a significant correlation between wound bed preparation (WBP) and wound closure.

Key findings revealed that wounds achieving WBP were 4.1 times more likely to close compared to those that did not (p = 0.0004). Notably, wounds failing to achieve WBP had a 90% probability of not healing. Early WBP achievement (within 14 days) showed a significantly increased healing likelihood (Relative Risk = 2.4). The study validates EscharEx's potential in accelerating wound bed preparation for improved healing outcomes.

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, will release its Q2 2025 financial results on Thursday, August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide corporate updates.

Investors can access the call via multiple channels including toll-free numbers for US and Israel, and an international dial-in. A webcast replay will be available in the Investors section of MediWound's website after the call.

MediWound (NASDAQ: MDWD) reported Q1 2025 financial results and provided corporate updates. The company generated $4.0 million in revenue for Q1 2025, down from $5.0 million in Q1 2024, and reported a net loss of $0.7 million ($0.07 per share). Key developments include: Their VALUE Phase III trial for EscharEx in venous leg ulcers is progressing with 216 patients across 40 sites in the U.S. and Europe. The company has secured collaborations with major wound care companies including Solventum, Mölnlycke, MIMEDX, and Kerecis. NexoBrid continues to gain traction with nearly 60 burn centers ordering the product, showing a 207% year-over-year increase in revenue. The company's new manufacturing facility expansion is on track for full operational capacity by end-2025, expected to increase production capacity sixfold. The company maintains a strong financial position with $38.7 million in cash and equivalents as of March 31, 2025, and reaffirmed its full-year 2025 revenue guidance of $24 million.

MediWound (NASDAQ: MDWD) published a post hoc analysis in Wounds journal comparing their EscharEx® treatment to SANTYL® for venous leg ulcers (VLUs). The analysis, based on Phase II ChronEx trial data, demonstrated superior clinical performance of EscharEx over SANTYL, the only FDA-cleared enzymatic debridement agent currently available.

Key findings showed that 63% of EscharEx patients achieved complete debridement at 2 weeks versus 0% in the SANTYL group. The median time to debridement was 9 days for EscharEx, while SANTYL did not achieve this milestone. Wound Bed Preparation was achieved by 50% of EscharEx patients in 2 weeks compared to 0% with SANTYL. Notably, wound closure rates were 33% for EscharEx versus 25% for SANTYL, with significantly faster mean time to closure (48 days vs. 76 days). Both treatments showed similar safety profiles, though deep wound infection rates were lower in the EscharEx group (11% vs. 38%).

MediWound Ltd. (NASDAQ: MDWD), a leader in enzymatic therapeutics for tissue repair, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 21, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time following the results release.

Investors can access the call through various channels including toll-free (1-844-676-8833), Israel (1-80-921-2373), and international (1-412-634-6869) numbers. A webcast replay will be available in the Investors section of MediWound's website after the call.